Form 8-K - Current report:
SEC Accession No. 0001434647-26-000067
Filing Date
2026-08-05
Accepted
2026-08-05 16:13:22
Documents
13
Period of Report
2026-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zvra-20260805.htm   iXBRL 8-K 28613
2 EX-99.1 zvra-20260805xex991earnings.htm EX-99.1 157835
6 zevralogoa.jpg GRAPHIC 6458
  Complete submission text file 0001434647-26-000067.txt   327730

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zvra-20260805.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zvra-20260805_lab.xml EX-101.LAB 21615
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zvra-20260805_pre.xml EX-101.PRE 12510
16 EXTRACTED XBRL INSTANCE DOCUMENT zvra-20260805_htm.xml XML 2714
Mailing Address 101 FEDERAL STREET BOSTON MA 02110
Business Address 101 FEDERAL STREET BOSTON MA 02110 (888) 958-1253
ZEVRA THERAPEUTICS, INC. (Filer) CIK: 0001434647 (see all company filings)

EIN.: 205894398 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36913 | Film No.: 261243675
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)